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Objective Spinocerebellar ataxia 36 (SCA36) is an
autosomal-dominant neurodegenerative disorder caused
by a large (>650) hexanucleotide GGCCTG repeat
expansion in the first intron of the NOP56 gene. The
aim of this study is to clarify the prevalence, clinical and
genetic features of SCA36.
Methods The expansion was tested in 676 unrelated
SCA index cases and 727 controls from France, Germany
and Japan. Clinical and neuropathological features were
investigated in available family members.
Results Normal alleles ranged between 5 and 14
hexanucleotide repeats. Expansions were detected in 12
families in France (prevalence: 1.9% of all French SCAs)
including one family each with Spanish, Portuguese or
Chinese ancestry, in five families in Japan (1.5% of all
Japanese SCAs), but were absent in German patients. All
the 17 SCA36 families shared one common haplotype
for a 7.5 kb pairs region flanking the expansion. While
27 individuals had typically long expansions, three
affected individuals harboured small hexanucleotide
expansions of 25, 30 and 31 hexanucleotide repeat-
units, demonstrating that such a small expansion could
cause the disease. All patients showed slowly progressive
cerebellar ataxia frequently accompanied by hearing and
cognitive impairments, tremor, ptosis and reduced
vibration sense, with the age at onset ranging between
39 and 65 years, and clinical features were
indistinguishable between individuals with short and
typically long expansions. Neuropathology in a
presymptomatic case disclosed that Purkinje cells and
hypoglossal neurons are affected.
Conclusions SCA36 is rare with a worldwide
distribution. It can be caused by a short GGCCTG
expansion and associates various extracerebellar
symptoms.
INTRODUCTION
Spinocerebellar ataxia (SCA) is a group of auto-
somal dominant neurodegenerative disorders clinic-
ally showing adult-onset progressive cerebellar
ataxia often complicated with various extracerebel-
lar signs or symptoms.1–3 SCA36 is caused by a
hexanucleotide GGCCTG repeat expansion in the
first intron of the NOP56 gene located on human
chromosome 20.4 In normal individuals, the repeat
is a polymorphic and complex sequence containing
slightly different hexanucleotides [AGCCTG],
[GGCCTG] repeat and [CGCCTG], and the entire
hexanucleotide repeats range in length between 3
and 14 units.4 5 In contrast, this GGCCTG repeat
was previously described as being highly expanded
in SCA36 patients, reaching between 6.8 kb and
∼18 kp pairs in Southern blot analysis, which was
roughly estimated to be between 650 and 2500
repeat-units.4–6 Given that the expansion lies in the
first intron (ie, a non-coding region) of NOP56,
SCA36 is regarded as one of the neurological dis-
eases caused by non-coding microsatellite repeat
expansion.7–10 Clinically, individuals with SCA36
show progressive cerebellar ataxia complicated by
motor neuron dysfunction, which is particularly
prominent in their tongues.4 So far, SCA36 has
been described only in western regions of Japan4 6
and the Costa da Morte region of Spain,5 suggest-
ing that there could be strong founder effects.
We conducted this study to clarify whether
SCA36 is seen beyond these founder populations
by investigating the SCA36 hexanucleotide repeat
in a cohort of 676 families comprising mostly
French, German and Japanese SCA index cases col-
lected across these countries. Besides genetic ana-
lysis, we investigated clinical and neuropathological
features in available family members to clarify how
this disease differs from other SCAs.
MATERIALS AND METHODS
Patient and control enrollment
We enrolled 676 index patients with SCA compris-
ing 270 French, 175 German and 231 Japanese
families. Eighty-seven per cent of the French fam-
ilies were of French Caucasian origin, while the
remaining 13% were the descendants of other
ethnic populations. The German cohort was
Caucasian, and the Japanese cases were of single
ethnicity. These index patients were all excluded
for previously known SCA mutations, which
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accounted for about 50% of all SCAs in their cohorts.1 11–13
All patients were collected from diverse areas of their respective
countries: Pitié-Salpêtrière University Hospital and through the
SPATAX network (France; http://spatax.wordpress.com/),
Ludwig-Maximilians-University Munich (Germany), University
of Tübingen (Germany) and Tokyo Medical and Dental
University ( Japan).12 A half of the Japanese SCA cohort was
collected from the Tokyo Metropolitan area, and thus the
present Japanese cohort is based on a population distinct from
the previous studies.4 6 Seven hundred and twenty-seven
healthy controls comprising 186 French, 304 German and 237
Japanese were also recruited.
From each participant, peripheral blood was drawn after
obtaining informed consent following bioethics guidelines from
each country. When index patients were found to be positive
for SCA36 expansions, other available family members were
further investigated. The study conformed to the tenets of the
Declaration of Helsinki, and was ethically approved by each
institutional review board.
Mutation screening
The hexanucleotide repeat expansion was screened by both
repeat-primed PCR and PCR-fragment analyses using primer
pairs flanking the hexanucleotide repeat. The conditions of
these reactions were determined using a DNA sample from an
original patient with SCA36 (Pedigree B, II-3).4 Primer
sequences are shown online (see online supplementary table).
The forward primer used for the repeat-primed PCR and
PCR-fragment analyses (50-TTTCGGCCTGCGTTCGGG-30)
was set between the 6 bp (base-pairs) CGGGCG insertion/dele-
tion polymorphism (rs28970277)5 and the GGCCTG repeat
sequence, allowing us to detect only the hexanucleotide repeat
complex containing the GGCCTG repeat. The numbers of
repeat-units in selected individuals, both controls and SCA36
individuals with short expansions, were determined by cloning
in pCR-TOPO (Invitrogen, California, USA) followed by
sequencing analysis. PCR products were finally separated and
analysed in an ABI PRISM 3100 (Applied Biosystems) and 2%
agarose gel. Segregation of genotype and phenotype was
checked in all available family members. For every individual
discovered to harbour the expansion, the source of transmission
was analysed by tracing and identifying the parent who had
transmitted the mutation. Then the bias of parental gender in
massive contraction was determined.
Southern blot analysis was carried out in 10 selected SCA36
samples using Avr II (New England Biolabs, Ipswich,
Massachusetts, USA) and 0.8% agarose gel.8 A 900 bp probe
was synthesised from genomic DNA by PCR, as shown online
(see online supplementary table). Using this probe, normal con-
trols show a single 3.5 kb band.
Haplotype analysis
We investigated all available Japanese and French SCA36 indivi-
duals for the microsatellite markers D20S906, D20S179,
D20S113, D20S198, D20S842, AFMa049yd1, D20S181 and
D20S193.4 The genotypes were expressed with an allele num-
bering consistent with that of a previously published individual
(II-3 in Pedigree 3).4 In addition, eight informative single-
nucleotide polymorphism (SNP) markers within NOP56 were
further tested to assess the founder haplotype. Six SNPs were in
the 50-untranslated region (50-UTR) and two were in intron 3.
No informative SNPs were found in intron 2. We could recon-
struct SNP haplotypes in every SCA36 individual with long
expansion by using a forward primer ‘NOP56-50UTR-F’ in the
50-UTR and a reverse primer ‘NOP56 intron 3-R’ in intron 3
(see online supplementary table). This was because the normal
allele was specifically amplified in the presence of long hexanu-
cleotide repeat expansions. Allele frequencies were investigated
in Japanese (n=9) and French (n=10) control individuals.
Clinical investigations
Data on clinical features were collected by neurologists in
charge of each participant with SCA36. The clinical features
were retrospectively reviewed for three Japanese patients
(Chubu #1, #2 and Chugoku) and four French participants
(AAD-508 #5 and #7, AAD-681 #7 and #11), as they had
been examined long before the identification of the SCA36
mutation. The rest of the Japanese and all the French SCA36
patients were clinically re-analysed and summarised in one
common format. The correlation between the clinical features
and the length of the expansion was statistically analysed by
Welch’s test.
Neuropathological analysis
An autopsy was undertaken in the individual AAD-508 #7, who
died at the age of 83. This participant did not show obvious
neurological dysfunction. After formaldehyde fixation, multiple
samples of the brain were embedded in paraffin and sectioned at
a thickness of 5 mm. The spinal cord was not available. The sec-
tions were stained with H&E. Immunohistochemistry was per-
formed using the following primary antibodies: antiubiquitin
(Dako, rabbit polyclonal, diluted in phosphate buffered saline:
1/500), anti-TAR DNA-binding protein 43 (TDP-43) (Protein
Tech Group, rabbit polyclonal, 1/2000), antifused in sarcoma
(FUS) (Sigma, rabbit polyclonal, 10 μg/mL) and anti-p62 (MBL,
mouse monoclonal, 1/300). Appropriate positive-control and
negative-control specimens were also stained to check the stain-
ing conditions. The primary rabbit antibodies were detected with
appropriate secondary antibodies using the XT Ultraview DAB
system (Ventana, Oro Valley, Arizona, USA). The anti-p62 anti-
body was detected with the Vectastain ABC mouse IgG kit
(Vector Laboratories, Burlingame, California, USA), and visua-
lised by using Histofine Simple Stain DAB (Nichirei Bioscience,
Tokyo, Japan) according to the manufacturer’s protocol.
RESULTS
Molecular results
The PCR-fragment analysis revealed that normal repeats ranged
from 5 to 14 complex hexanucleotide repeat-units in our
cohorts of 727 control individuals. The distribution of normal
repeats was basically identical among French, German and
Japanese controls (see online supplementary figure 1). The most
common allele carried 9 complex hexanucleotide repeat-units
and the normal upper limit of our cohort was 14 complex hexa-
nucleotide repeats as described by García-Murias et al.5
The repeat-primed PCR analysis disclosed GGCCTG repeat
expansions in 17 index cases from 17 families (12 from the
French cohort, including one individual each from Chinese,
Portuguese and Spanish families living in France and five
Japanese; figures 1 and 2A). Thus, SCA36 accounted for 1.9%
of all SCAs of the French cohort and 1.5% of all Japanese
SCAs, both including the families with already known mutations
in other SCA genes. No expansions were found in the German
cohort. Further investigations additionally revealed hexanucleo-
tide expansions in a total of 30 individuals with the SCA36
GGCCTG expansion.
On the PCR-fragment analysis, normal participants often
showed two different peaks (figure 2B). On the other hand,
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27 of the 30 SCA36 individuals showed single peaks within the
normal range, suggesting that these patients harbour typically
long expansions that hinder amplification by ordinary PCR
(figure 2C). The remaining three (two French [AAD 709 #15
and AAD 352 #6] and one Japanese [Kanto-1]) showed two
peaks on the PCR-fragment analysis, the larger one of which
was always mosaic and exceeded the normal repeat range
(figure 2D, E). Cloning and subsequent sequence analysis revealed
that the longer repeats ranged between 25 and 31 complex hexa-
nucleotide repeats containing 21 to 28 GGCCTG repeats: AAD
709 #15 (with 25 hexanucleotide repeats): 50-[AGCCTG]-
(GGCCTG)21-[CGCCTG]3-30; AAD 352 #6 (with 31 hexanu-
cleotide repeats): 50-[AGCCTG]-(GGCCTG)28-[CGCCTG]2-30;
Kanto-1 (with 26 hexanucleotide repeats): 50-[AGCCCG]-
(GGCCTG)23-[CGCCCG][CGCCTG]-30. There was no affected
individual without the expansion as far as the available DNA
samples were tested, supporting the theory that the expansion seg-
regated with the disease in all families examined. In addition, an
individual with a typically long expansion and another affected
individual with a short expansion were present in the same French
family AAD352 (figure 1). Southern blot analysis disclosed that
the typically long expansion ranged between 800 and 2000
repeats (figure 2F). In addition, a broad band was demonstrated
from individuals harbouring short expansions, supporting the
theory that the expansions in these three participants were indeed
very small. All three individuals with short expansions (AAD-709
#15, AAD-352 #6 and Kanto-1) had received the disease from
their mothers (figure 1). However, it was not certain whether
the short expansions in the three individuals were from contrac-
tions, as we could not directly test the transmission in a parent-
offspring basis.
As we found SCA36 families from diverse ethnic origins, we
tested if SCA36 families harboured different haplotypes.
Genotype data from all available participants are summarised in
table 1. We found a common haplotype in all SCA36 individuals
irrespective of the ethnicity ( Japanese, Chinese, Portuguese and
French) for the SNP markers flanking the GGCCTG repeat in
NOP56 and for D20S198, only 7 kb away from the repeat. On
the other hand, haplotypes diverged significantly among the
families when we tested distant microsatellite DNA markers. For
example, D20S842, which showed a conserved allele among
Spanish SCA36 families,5 was discordant within the Japanese as
well as the French SCA36 families. These data imply that
SCA36, even with different ethnic origins, is associated with a
common haplotype close to the repeat. However, the SNP
haplotype common to all SCA36 families was also found in
26% of control chromosomes, and the frequency of allele 3
for D20S198 was 28% in Japanese controls and 55% in
French controls.
Clinical results
Clinical information was available from 28 individuals with the
expansion: 20 French and 8 Japanese (table 2). Among these,
three French individuals (AAD-508 #5, #7 and SAL-334 #9)
did not complain of any neurological disturbances, and were
thus excluded from the evaluation of clinical features. The age
of onset defined by the time when patients started to notice
cerebellar signs was 50.4±7.2 (SD) years, with a range of 39–65
years in the remaining 25 individuals. The cardinal clinical
feature was progressive cerebellar ataxia in all 25 symptomatic
individuals. Other frequent involvements included (1) hearing
impairment (6 French, 1 Chinese, 1 Portuguese and 7 Japanese,
a frequency of 60% among the 25 individuals), (2) postural
tremor (5 French and 2 Japanese; 28%), (3) ptosis (2 French
and 4 Japanese; 24%) and (4) cognitive impairment (3 French,
1 Spanish and 2 Japanese; 24%). Reduced vibration sense was
seen in 13 (6 French, 1 Portuguese and 6 Japanese; 52%).
Figure 1 Twelve French and 4 Japanese SCA36 families. The French
families consisted of 9 originally French kindred, one for each of
Portuguese, Spanish and Chinese descendants (the origins are not
shown to protect from personal identification). In the family AAD-352,
an individual with short expansion (#6) and his nephew (#18) with
typically long expansion are observed. Note that all three individuals
with short expansions (French AAD-352 #6, French AAD-709 #15 and
Japanese Kanto-1) had inherited the disease from their mothers. Owing
to ethical reasons, pedigree structures are simplified and genders of
some participants are anonymised. The pedigree information on the fifth
Japanese family was not available and thus not shown in this figure.
*Genetically tested; grey symbols: individuals without any complaints of
neurological disturbances, or those not examined by the authors.
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Evidence of lower motor neuron signs, such as tongue atrophy
and bulbar signs, was present in two French symptomatic parti-
cipants and five Japanese individuals (28%). On ancillary inves-
tigations, eight patients (4 French and 4 Japanese) who were
tested by peripheral nerve conduction study revealed reduced
sensory action potentials (SNAPs) with an overall frequency of
32%, suggesting that peripheral nerves can be affected by this
disease. Among the 14 participants examined by MRI, all
showed cerebellar atrophy (100%), with some cases also exhibit-
ing additional atrophy in the cerebrum (n=2; 14.3%) and in
the brainstem (n=4; 28.6%).
Regarding the genotype-phenotype correlations, the average
age at onset in the three individuals with short expansions
(57.3 years) tended to be later than that of patients with long
expansions (49.4 years, n=22). However, this difference was
not significant (p=0.408, Welch’s test).
Neuropathological findings
The neuropathological examination of patient AAD508#7
revealed diffuse cortical cerebellar atrophy. Histology demon-
strated a mild Purkinje cell loss with Bergmann’s gliosis
(figure 3A, black arrow), distorted dendrites and atrophic cell
body of the Purkinje cells (figure 3B, white arrows) and swel-
lings of Purkinje cell axons called ‘torpedo’ (figure 3B, a black
arrow). The hypoglossal nucleus (outlined by four arrows in
figure 3C) showed a mild neuronal loss and gliosis (figure 3D).
No alteration was evident in the cochlear and pontine nuclei.
Ubiquitin, TDP43, FUS and p62 immunohistochemistry were all
negative. Neuropathological changes compatible with
Alzheimer’s disease, such as numerous amyloid plaques of the
Braak and Braak Stage IV,14 were also seen.
DISCUSSION
The present study disclosed that SCA36 is not confined to the
western region of Japan4 and the Costa da Morte region of
Spain,5 but instead shows a global distribution, including indivi-
duals of French, Portuguese and Chinese ancestry. Nevertheless,
the frequency of SCA36 was low in both Japanese (1.5%) and
French (1.9%) SCA cohorts: this level was much lower than the
prevalence in Okayama, Japan (3.6%)4 and in Galicia, Spain
(6.3%).5 The absence of SCA36 patients in the present German
cohort may suggest that SCA36 has an uneven distribution in
Europe. Despite their diverse ethnicity, all the present SCA36
families showed a single haplotype for the tested SNPs in
NOP56 and the nearby microsatellite D20S198, whereas their
haplotypes diverged for distant microsatellite markers including
D20S842, which was conserved in the Spanish families in
Galicia.5 This suggests that SCA36 repeat expansions arose from
one or a few founder chromosomes in ancient times. Compared
to SCA10, another non-coding repeat expansion disorder with a
strong founder effect particularly prevalent in Central and
South American countries,15 SCA36 repeat expansion might
have arisen in a much ancient era. However, we noted that the
founder SNP haplotype was still common with a frequency of
26% of our control French and Japanese chromosomes.
Therefore, it is necessary to find markers that are tightly linked
to SCA36 individuals and then to test them on larger numbers
of SCA36 families in order to draw a more definitive conclusion
on founder effects.
This study also disclosed that SCA36 shows Purkinje cell
dropout and neuronal loss of the hypoglossal nucleus, consistent
Figure 2 SCA36 hexanucleotide repeat expansions. (A) Typical
attenuating peaks (arrow) of a hexanucleotide (GGCCTG) repeat
expansion detected by the repeat-primed PCR analysis. (B) The PCR
fragment analysis in a normal control showing two peaks
corresponding to normal heterozygous alleles. (C) The same PCR
fragment analysis on an SCA36 individual with a heterozygous long
expansion showing only a single peak from a normal allele. The PCR
reaction fails to amplify a typically long expansion, and thus the
expansion is not detected by this method. (D) Demonstration of a short
expansion (an arrowhead). Notice that the short expansion is mosaic,
having six different peaks. (E) Short expansion in a Japanese individual
(Kanto-1) (middle lane, upper band) is clearly seen in 2% agarose gel
electrophoresis. The 100 base-pair size marker is separated in the right
lane. Normal control (NC). (F) Southern blotting analysis detects
typically long GGCCTG expansions in 4 SCA36 participants (‘typical
SCA36 patients’) ranging between 8 and 15 kp pairs as well as short
clear bands at approximately 3.5 kb. NC showed only a single band at
3.5 kb. The expanded allele in the third SCA36 sample from the right is
faint, which may suggest a highly mosaic expansion. An individual with
short expansion ( Japanese Kanto-1) shows a blurred and slightly
broader band of normal size.
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Table 1 Haplotype information on Japanese and French SCA36 families
Distance from the mutation −1130 kb −660 kb −600 kb −429 bp −348 bp −289 bp −272 bp −170 bp −161 bp 0 + “705 bp + ‘801 bp +7 kb +52 kb +460 kb +640 kb +780 kb
Marker in the
chromosome 20p13 telomere D20S906 D20S179 D20S113 rs6083954 rs2073196 rs6083956 rs2073195 rs6115305 rs4815467
GGCCTG





The common haplotype in the
Okayama SCA36
family ref. 4 (#II-3)
2/3
not shared
2 3 T G T G G C long C G 3 3 3 1 4/5
not shared
Japanese SCA36 individuals
1 Kinki-1 2/3 2/1 3/3 T G T G G C long C G 3/8 3/13 3/3 1/1 4/7
2 Kanto-1 1/3 2/5 3/5 T G T G G C short C G 3/2 3/8 3/2 1/10 5/5
3 Chubu-2 2/2 1/1 3/6 T G T G G C long C G 3/3 3/1 3/2 1/6 3/7
4 Shikoku-1 2/2 1/8 1/2 T G T G G C long C G 3/3 4/5 2/3 1/4 7/8
French SCA36 families
AAD508–5 2/4 1/1 1/1 T G T G G C long C G 3/3 4/5 3/7 3/11 8/7
1 AAD508-7 2/2 1/1 1/1 T G T G G C long C G 3/7 4/4 3/6 3/11 8/6
AAD508-15 2/2 1/1 1/1 T G T G G C long C G 3/4 4/2 3/2 3/2 8/4
AAD508-17 2/2 1/1 1/1 T G T G G C long C G 3/7 4/4 3/6 3/3 8/5
2 AAD344-9 2/5 1/1 1/1 NA NA NA NA NA NA long NA NA 3/7 4/12 3/2 3/4 8/5
3 AAD682-9 2/3 1/1 1/4 NA NA NA NA NA NA long NA NA 3/3 4/4 3/6 3/11 8/7
4 AAD681-11 2/3 1/1 1/1 NA NA NA NA NA NA long NA NA 3/2 4/5 3/3 3/11 5/9
5 AAD814-13 3/5 1/1 1/5 NA NA NA NA NA NA long NA NA 3/7 4/2 3/3 3/3 5/6
6 AAD379-5 2/8 1/1 1/1 NA NA NA NA NA NA long NA NA 3/2 4/5 4/6 3/3 5/6
7 AAD803-22 2/3 1/6 1/6 NA NA NA NA NA NA long NA NA 3/2 6/9 4/6 3/3 5/5
8 AAD709-15 3/4 1/6 1/5 NA NA NA NA NA NA short NA NA 3/3 6/6 4/2 3/3 5/7
SAL334-3 5/2 1/1 1/1 T G T G G C long C G 3/8 6/8 7/2 11/1 7/5
SAL334-7 5/3 1/2 1/1 NA NA NA NA NA NA long NA NA 3/3 6/4 7/3 11/3 7/5
SAL334-9 5/3 1/2 1/1 NA NA NA NA NA NA long NA NA 3/3 6/4 7/3 11/3 7/5
9 SAL334-13 5/2 1/1 1/1 NA NA NA NA NA NA long NA NA 3/8 6/8 7/2 11/1 7/5
SAL334-17 5/3 1/2 1/1 NA NA NA NA NA NA long NA NA 3/3 6/2 7/6 11/11 7/6
SAL334-19 5/3 1/1 1/5 NA NA NA NA NA NA long NA NA 3/3 6/8 7/6 11/3 7/7
10 AAD352-6 3/4 1/6 5/4 T G T G G C short C G 3/3 8/4 3/4 1/3 4/10
AAD352-18 3/4 1/6 5/3 T G T G G C long C G 3/7 8/5 3/6 1/3 5/11
11 AAD829-3 2/2 1/1 3/3 T G T G G C long C G 3/6 5/6 2/2 3/5 3/8
The location of the GGCCTG repeat is shaded in light blue. The Japanese founder haplotype in the Okayama family (see reference #4) and its extent shared in other families are shown by bold boxes. The haplotype shared by Japanese families is coloured
in grey. The French haplotypes are coloured in yellow (the most common one), green and purple. The allele frequency of ‘3’ in D20S198 is 28% in the Japanese (+) control population and 55% in the French (*) control population.
NA stands for single-nucleotide polymorphic markers that have not been analysed.
The 5th Japanese family and the 12th French SCA36 family (SAL-367) were not able to assess their haplotype and therefore are not listed in table 1.
































































AAD-508 5 NA F 80 No
complaint
0 NA Absent Absent Increased Normal Limited gaze No No Yes No Not evident NA
7 NA F 83 No
complaint
0 NA Absent Absent Normal Normal Normal No No No No Not evident NA Autopsy
Case
15 1080 M 56 (52) Unknown 4 NA Two canes Absent Increased Normal Normal Yes No No No Not evident Mild sensory motor
neuropathy (54)
17 NA F 62 (59) Instability
dysarthria
3 NA Cannot run Absent Increased Decreased Limited gaze Deafness No No No Not evident NA
AAD-344 9 NA M 63 (53) Instability 4 NA Walking
with aids
(62)




Deafness No No No Not evident NA
AAD-682 9 2000 F 54 (40) Cramps
Instability




No Yes No No Not evident NA
AAD-681 7 NA F 79 (42) Instability Unknown NA Unknown Unknown Unknown Unknown Unknown Unknown NA NA NA Unknown NA
11 1500 F 59 (56) Instability 0 NA Unknown Unknown Unknown Unknown Unknown Unknown NA N.A Yes Unknown NA
AAD-814 13 NA F 53 (47) Instability
decreased
hearing
3 25 (57) Cannot run Mild Increased Decreased Hypometric
saccades
ptosis
Yes No Yes Yes Not evident Bilateral carpal
tunnel syndrome
(53)
AAD-379 5 NA M 54 (51) Instability
dysarthria
2 NA Mild Mild Increased Normal Saccadic
pursuit
Yes No No Yes Not evident NA
AAD-803 22 1000 F 60 (59) Instability 4 18 (60) Walking
with aids
(53)
Moderate Increased Decreased Saccadic
pursuit
Yes Yes Yes No Not evident NA
AAD-709 15 21 F 54 (44) Diplopia 3 NA Cannot run
(52)









Cannot run Mild Increased Normal Hypermetric
saccades
No No No No Not evident Mild sensory motor
neuropathy (61)
Rigidity
7 NA F 59 (52) Instability 2 NA Mild gait Absent Abolished Normal Normal No No No No Not evident NA
9 NA F 53 No
complaint
1 NA Mild Absent Increased Normal Normal No Yes No No Not evident NA
13 NA M 49 (46) Tremor 1 NA Mild Absent Increased Decreased Normal No Yes No No Not evident NA Cramps
AAD-352 6 28 M 73 (63) Instability 2 NA Mild Severe Increased Decreased Normal No No No No Not evident NA
18 NA M 50 (43) Instability 4 NA Walking
with aids
(47)
Severe Normal Normal Nystagmus No Yes No No Not evident NA
AAD-829 3 NA M 62 (53) Instability
diplopia




Yes No No No Not evident NA
SAL-367 9 NA F 59 (40) Abnormal
behaviour
5 NA Wheel chair Severe Abolished Normal Limited gaze
optic pallor

























































Shikoku 1 850 F 58 (54) Instability 3 15 (59) Walking
with aids
(57)
Mild Increased Normal Saccadic
pursuit
diplopia









2 NA F 64 (49) Instability 6 20 (64) Unable to
walk (62)
Moderate Normal Normal Saccadic
pursuit





Kinki 1 1250 M 67 (42) Instability 6 18 (68) Cannot
stand
Moderate Increased Decreased Facial
weakness












2 NA M 43 (39) Instability 5 11 (44) Walking
with canes
Mild Increased Decreased Normal No No No No Not evident NA
Kanto 1 27 M 66 (65) Dizziness 2 8 (65) Very mild
ataxia
Mild Increased Decreased Slightly
saccadic
pursuit
Yes No No No Not evident NA
Chubu 1 NA F 65 (57) Instability 4 NA One cane
(65)








2 1000 F 57 (54) Instability 3 NA Cannot run
(54)
















3 NA M 68 (58) Instability 2 10 (68) One cane
(68)
Mild Decreased Decreased Ptosis, Gaze
nystagmus
Yes Yes NA NA Not evident Sensory axonopathy
in medial plantar
nerve
The three participants without complaints (AAD-508 #5, #7 and SAL-334 #9) are shaded and are excluded for calculating frequencies of neurological signs.
Stage=0: normal; 1: no functional handicap but signs at examination; 2: mild, able to run, walking unlimited; 3: moderate, unable to run, limited walking without aid; 4: severe, walking with one stick; 5: walking with two sticks; 6: unable to walk,
requiring wheelchair; 7: confined to bed.
The confirmed age is the age at examination unless described specifically in parentheses.
NA, not assessed.

























with the first autopsy case of SCA36.16 What is important from
the present case is that the patient presented evidence of neuro-
degeneration in the Purkinje cell and hypoglossal nucleus
without showing obvious neurological signs. It would become
important in future to accumulate knowledge on the extent of
neurodegeneration in a pre-manifesting stage for deciding when
to administer fundamental treatment. Another important
finding is that there were no obvious neuronal cytoplasmic
inclusions (NCIs) or nuclear inclusions (NNIs) characterising
the neuropathology of amyotrophic lateral sclerosis (ALS)17 as
far as we examined by ubiquitin, TDP43, FUS and p62 immu-
nohistochemistry. It has been shown that the frontotemporal
lobar dementia and ALS (FTD-ALS) caused by C9orf72 hexanu-
cleotide GGGGCC repeat expansion shows the accumulation of
ubiquitin-immunoreactive and p62-immunoreactive NCIs, not
only in the anterior horn cells in the spinal cord, but also in the
cerebellar granule cells.18 Large ubiquitin-positive NIIs seen in
fragile X-associated tremor/ataxia syndrome (FXTAS)19 were
also not detected in this case. These findings may suggest that
SCA36 pathological features are distinct from those of non-
coding repeat expansion disorders. Future investigations should
search for abnormal RNA structures (‘RNA foci’) in these
affected neuronal cells, as have been detected in other related
diseases caused by repeat expansions in introns: myotonic dys-
trophy type 2 (DM2),7 SCA1020 and SCA31.8 21
The most intriguing finding in this study is that the short hex-
anucleotide expansion of 25–31 repeat-units, slightly exceeding
the upper limit in controls (14 repeat-units), is seen in some
affected individuals. This indicates that such short expansions
could cause the disease, although we cannot exclude a possibil-
ity that repeat expansions are much longer in the nervous
system than in the blood. As the number of patients with short
expansions was very small in the present cohort, the difference
in the age of onset between those with short and typically long
expansions did not reach a significant level. Further studies
including larger numbers of individuals with short expansions
are thus necessary. In all the three individuals with short expan-
sions, it was conceivable that the disease had been transmitted
from their mothers, as in a previous description.5 However, we
could not directly investigate parent-offspring pairs to confirm
maternal bias for repeat contraction. If this was the case, SCA36
would be another example of such contraction after DM122 and
a mother-to-daughter repeat contraction in Huntington’s
disease.23 24 Precise knowledge of such parental bias is import-
ant for clinical situations, such as genetic counselling, as well as
for determining the mechanism of repeat expansion.
Interestingly, short GGGGCC repeat expansion in C9orf72
has been identified in patients with FTD25 and Parkinson’s
disease,26 suggesting a common feature in C9orf72 and NOP56
repeat expansions. What seems distinct from the C9orf72-
associated neurological diseases is the fact that patients with
short expansions in NOP56 do not obviously differ in their phe-
notypes from those with long expansions, while patients asso-
ciated with expansions in C9orf72 show a wide spectrum of
clinical symptoms depending on the length of the expan-
sion.9 10 25 26 As such, how can we explain that the short and
long GGCCTG expansions in NOP56 cause similar pheno-
types? We investigated whether a short expansion of 21
GGCCTG repeats shows any difference in the likelihood of
forming hairpin structures compared with the normal 14
repeats using a computer prediction algorithm.27 The 21-repeat
allele was indeed predicted to form a double-stranded hairpin
more efficiently than the 14-repeat allele, but with only a small
difference. We need to recognise that the threshold of being a
Figure 3 Neuropathology of an asymptomatic 83-year-old female carrier. The cerebellum (A and B) and the tegmentum of the medulla oblongata
(C and D) stained with H&E. (A) A mild depletion of Purkinje cells is seen. The black arrows indicate Bergmann’s gliosis in a region where Purkinje
cells are depleted. (B) A higher magnification view showing dendrites and the cell body of Purkinje cells (white arrows). A torpedo in the granule
cell layer is indicated by a black arrow. (C) A low magnification view showing the hypoglossal nucleus (surrounded by black arrows). (D) A high
magnification view of the hypoglossal nucleus. Motor neurons are reduced in number. Size bar: A and C=200 mm; B and D=20 mm.
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pathogenic repeat is much lower than was previously being
thought. It is also possible that the mechanism underlying
SCA36 is similar to the RAN translation mechanism proposed
in DM1, SCA828 and recently confirmed in C9orf7229 30-
associated FTD/ALS and FXTAS.31
In summary, SCA36 is present in various ethnic backgrounds,
by the sharing of a common linked haplotype. Clinical varia-
tions with regard to lower motor neuron involvement, ptosis,
hearing and cognitive impairments, tremor and reduced vibra-
tion sense suggest that this disease should be tested in all cases
with progressive late-onset cerebellar ataxia. To do this, the
PCR-fragment analysis as well as the repeat-primed PCR test are
needed. Knowledge that a short expansion of at least 25 hexa-
nucleotide repeats containing a stretch of 21 GGCCTG can
cause the disease is an important source of information regard-
ing genetic diagnosis and for future deciphering of SCA36
pathogenesis.
Author affiliations
1Department of Neurology and Neurological Sciences, Graduate School, Tokyo
Medical and Dental University, Tokyo, Japan
2Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S1127,
Paris, France
3Inserm, U1127, Paris, France
4Cnrs, UMR 7225, Paris, France
5AP-HP, Groupe Hospitalier Pitié-Salpêtriére, Departement of Genetics and
Cytogenetics, Paris, France
6Ecole Pratique des Hautes Etudes, Groupe de Neurogénétique, Paris, France
7Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain
Research, Tübingen, Germany
8German Centre of Neurodegenerative Diseases, University of Tübingen, Tübingen,
Germany
9Laboratoire de Neuropathologie R. Escourolle, Groupe Hospitalier Pitié-Salpêtrière,
47 Blvd de l’Hôpital, Paris, France
10Pathology and Biochemistry, Groupement Hospitalier Est, Hospices Civils de Lyon/
Claude Bernard University, Lyon, France
11Neurology Department, Hôpital Pierre Wertheimer, Lyon, France
12Neurology D, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France
13Lyon Neuroscience Research Center, INSERM U1028/CNRS UMR 5292, Lyon,
France
14Université de Lyon—Université Claude Bernard Lyon 1, Lyon, France
15Institute of Epidemiology I, Helmholtz Zentrum München—German Research
Center for Environmental Health, Neuherberg, Germany
16Institute of Medical Informatics, Biometry and Epidemiology, Chair of
Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany
17Unit for Molecular Epidemiology, Helmholtz Zentrum München—German Research
Center for Environmental Health, Neuherberg, Germany
18Institute of Medical Genetics and Applied Genomics, University of Tübingen,
Tübingen, Germany
19Neurology Service, Hyogo Brain and Heart Center at Himeji, Himeji, Hyogo, Japan
20Department of Clinical Neuroscience, The University of Tokushima Graduate
School, Tokushima, Japan
21Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-Universität
München, Munich, Germany
22German Network for Mitochondrial Disorders (mitoNET)
23DZNE—German Center for Neurodegenerative Diseases, Munich, Germany
24German Center for Vertigo and Balance Disorders, Munich, Germany
Acknowledgements The authors are grateful to Professor Koji Abe (Okayama
University, Japan) for sending an original SCA36 positive DNA sample, Dr Tohru
Matsuura for his technical advice and Dr Christopher E. Pearson (the Hospital for
Sick Children, Toronto) for critically reading the manuscript. The authors are also
grateful to Professor Bauer for establishing and supervising the sequencing and
analysis of the large share of German samples, Drs Sylvie Forlani, Alain Autret, Alla
Frances, Thibault Lalu, Emmanuel Broussolle, Bruno Moulard and Stéphane Berroir
for patient referral and to the DNA and cell bank of CR-ICM for blood sample
treatment and DNA extraction and storage. Drs Nobuo Sanjo and Takayoshi
Kobayashi are also acknowledged for their clinical investigations on two SCA36
patients. The authors thank Dr Kiyobumi Ota for performing immunohistochemistry.
Contributors MO examined the patients, investigated the DNA samples and wrote
the manuscript. GS managed the French DNA samples, analysed the genetic data
and wrote the manuscript. MS examined the Tübingen-based patients, collected the
DNA, selected the patients for screening and wrote the manuscript. M-L, Monin,
AV, VD, YK and YI examined the patients. CD performed the neuropathological
study and partially wrote the manuscript. NS examined the patients and investigated
the DNA samples with MO. NS performed the neuropathological study. CT managed
the DNA samples and analysed the genetic data. H-EW collected the Munich-based
German control samples with TI. TI collected the Munich-based German control
samples with H-EW. JH analysed the large share of German DNA samples. HM
co-ordinated the study. LS examined the Tübingen-based patients and collected the
DNA. TK collected the German samples in Munich and wrote the manuscript. AB
collected the French samples with GS and AD, coordinated the whole study and
wrote the manuscript. KI collected the Japanese samples, examined the patients,
analysed the DNA samples with MO and NS, coordinated the whole study and
wrote the manuscript. AD examined the patients, collected and arranged the French
samples and wrote the manuscript. All authors have read and approved the content
of the manuscript.
Funding This study was financially supported by the Verum Foundation (to AB and
GS), the French association ‘Connaitre les Syndromes Cérébelleux’ (to GS and AD),
the Programme Hospitalier de Recherche Clinique (to AD), the Fondation Roger de
Spoelberch (to AB), the Agence Nationale de la Recherche (to GS), the European
Union (7th Framework program, Omics call), the Japanese Ministry of Education,
Sports and Culture (KI and HM), the Strategic Research Program for Brain Sciences
(‘Understanding of molecular and environmental bases for brain health’) (HM), the
Japan Society for the Promotion of Science ( JSPS) (KI and HM), Core Research for
Evolutional Science and Technology (CREST), Japan Science and Technology Agency
( JST) (HM), the Health and Labour Sciences Research Grants on Ataxic Diseases (KI
and HM) of the Japanese Ministry of Health, Labour and Welfare, Japan, and the
German Federal Ministry of Education and Research (German Center for Vertigo and
Balance Disorders, grant 01 EO 0901, to TK). CT received a fellowship from the
French Ministry for Research. This study also benefited from funding from the
programme ‘Investissements d’avenir’ ANR-10-IAIHU-06 (to the Brain and Spine
Institute, Paris).
Competing interests GS received grants from the French National Agency for
Research, the Verum Foundation and from the association Connaitre les Syndromes
Cérébelleux. MS received research grants from the Volkswagen Stiftung and the
Robert Bosch Stiftung, travel grants from the Movement Disorders Society and
AtaxiaUK/Ataxia Ireland, and consulting fees from Actelion Pharmaceuticals Ltd.
CT received a fellowship from the French Ministry for Research and the Association
Connaitre les Syndromes Cérébelleux. HM has received research grants from the
Health and Labour Sciences Research Grants on Ataxic Diseases, Ministry of Health,
Labour and Welfare, Japan, the Grants-in-Aid for Scientific Research, Japan Society
for the Promotion of Science, Japan, the Strategic Research Program for Brain
Sciences by the Ministry of Education, Culture, Sports, Science and Technology of
Japan, and Core Research for Evolutional Science and Technology (CREST), Japan
Science and Technology Agency ( JST), Saitama, Japan. LS received research grants
from the Deutsche Forschungsgemeinschaft (SCHO754/4-1 and SCHO754/5-1),
grants of the German Research Council (BMBF) to Leukonet (01GM0644) and
mitoNET (01GM0864) and E-RARE grants to EUROSPA (01GM0807) and RISCA
(01GM0820). He further received funding from the HSP-Selbsthilfegruppe
Deutschland eV. TK has been a principal investigator or investigator on
industry-sponsored trials funded by Santhera Pharmaceuticals Ltd (idebenone in
LHON, idebenone in Friedreich ataxia) and by H Lundbeck A/S (carbamylated
erythropoietin in Friedreich ataxia). He has received research support from
government entities (German Research Foundation; German Federal Ministry of
Education (German Center for Vertigo and Balance Disorders, grant 01 EO 0901)
and Research; European Commission 7th Framework Programme) and from
commercial entities (Santhera Pharmaceuticals Ltd; Actelion Pharmaceuticals Ltd;
H. Lundbeck A/S). He has been serving on scientific advisory boards for commercial
entities (Santhera Pharmaceuticals Ltd; Actelion Pharmaceuticals Ltd) and for
non-profit entities (Center for Rare Diseases Bonn, Germany; Hoffnungsbaum e.V.,
Germany). He has received speaker honoraria and travel costs from commercial
entities (Dr Willmar Schwabe GmbH & Co. KG; Eisai Co., Ltd.; Santhera
Pharmaceuticals Ltd; Actelion Pharmaceuticals Ltd; Boehringer Ingelheim Pharma
GmbH & Co. KG, GlaxoSmithKline GmbH & Co.KG). He has been doing
consultancies for the Gerson Lehrman Group, USA and FinTech Global Capital,
Japan. He has been serving as a section editor for BMC Medical Genetics from
2011. AB has received research grants from the European Union (contract
LSHM-CT-2004-503304/E040044DD), from E-RARE (to EUROSPA project), from
Fondation Roger de Spoelberch and from the Verum Foundation. The French group
has also received funding from the programme ‘Investissements d’avenir’
ANR-10-IAIHU-06 (to the Brain and Spine Institute, Paris). KI received research
grants from the Kobayashi Magobei Research Foundation, Mitsubishi Zaidan
Research Foundation, Grants-in-Aid for Scientific Research, Japan Society for the
Promotion of Science, Japan, and Grants-in-Aid for the Scientific Research on
Innovative Areas, ‘Exploring molecular basis for brain diseases based on personal
genomics’, the Ministry of Education, Culture, Sports, Science and Technology of
Japan. AD: received research grants from the Programme Hospitalier de Recherche
Clinique (contracts AOM03059/R05129DD and AOM10094), the association
Connaitre les Syndromes cérébelleux and the French National Agency for Research.
994 Obayashi M, et al. J Neurol Neurosurg Psychiatry 2015;86:986–995. doi:10.1136/jnnp-2014-309153
Neurogenetics
group.bmj.com on May 3, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
Ethics approval Paris-Necker University Hospital, Ludwig-Maximilians-University
Munich (Germany), University of Tübingen (Germany) and Tokyo Medical and Dental
University ( Japan).
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1 Dürr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and
beyond. Lancet Neurol 2012;9:885–94.
2 Lee YC, Dürr A, Majczenko K, et al. Mutations in KCND3 cause spinocerebellar
ataxia type 22. Ann Neurol 2012;72:859–69.
3 Serrano-Munuera C, Corral-Juan M, Stevanin G, et al. New subtype of
spinocerebellar ataxia with altered vertical eye movements mapping to chromosome
1p32. JAMA Neurol 2013;70:764–71.
4 Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG
hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia
accompanied by motor neuron involvement. Am J Hum Genet 2011;89:121–30.
5 García-Murias M, Quintáns B, Arias M, et al. ‘Costa da Morte’ ataxia is
spinocerebellar ataxia 36: clinical and genetic characterization. Brain
2012;135:1423–35.
6 Sugihara K, Maruyama H, Morino H, et al. The clinical characteristics of
spinocerebellar ataxia 36: a study of 2121 Japanese ataxia patients. Mov Dis
2012;27:1158–63.
7 Wojciechowska M, Krzyzosiak WJ. Cellular toxicity of expanded RNA repeats: focus
on RNA foci. Hum Mol Genet 2011;20:3811–21.
8 Sato H, Amino T, Kobayashi K, et al. Spinocerebellar ataxia type 31 is associated
with “inserted” penta-nuclotide repeats containing (TGGAA)n. Am J Hum Genet
2009;85:544–57.
9 DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC
hexanucleotide repeat in noncoding region of C9orf72 causes chromosome
9p-linked FTD and ALS. Neuron. 2011;72:245–56.
10 Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion
in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron
2011;72:257–68.
11 Ishikawa K, Dürr A, Klopstock T, et al. Pentanucleotide repeats at the spinocerebellar
ataxia type 31 (SCA31) locus in Caucasians. Neurology 2011;77:1853–5.
12 Obayashi M, Ishikawa K, Izumi Y, et al. Prevalence of inositol 1, 4, 5-triphosphate
receptor type 1 gene deletion, the mutation for spinocerebellar ataxia type 15,
in Japan screened by gene dosage. J Hum Genet 2012;57:202–6.
13 Synofzik M, Beetz C, Bauer C, et al. Spinocerebellar ataxia type 15: diagnostic
assessment, frequency, and phenotypic features. J Med Genet 2011;48:407–12.
14 Braak H and Braak E. Diagnostic criteria for neuropathologic assessment of
Alzheimer’s disease. Neurobiol Aging 1997;18(4 Suppl):S85–8.
15 Almeida T, Alonso I, Martins S, et al. Ancestral origin of the ATTCT repeat
expansion in spinocerebellar ataxia type 10 (SCA10). PLoS ONE 2009;4:e4553.
16 Ikeda Y, Ohta Y, Kobayashi H, et al. Clinical features of SCA36. A novel
spinocerebellar ataxia with motor neuron involvement (Asidan). Neurology
2012;79:333–41.
17 Al-Chalabi A, Jones A, Troakes C, et al. The genetics and neuropathology of
amyotrophic lateral sclerosis. Acta Neuropathol 2012;124:339–52.
18 Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal
dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC
expansion in C9orf72. Brain 2012;135:765–83.
19 Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated
tremor/ataxia syndrome (FXTAS). Brain 2006;129:243–55.
20 White MC, Gao R, Xu W, et al. Inactivation of hnRNP K by expanded intronic
AUUCU repeat induces apoptosis via translocation of PKC[delta] to mitochondria in
spinocerebellar ataxia 10. PLoS Genet 2010;6:e1000984.
21 Niimi Y, Takahashi M, Sugawara E, et al. Abnormal RNA structures (RNA foci)
containing a penta-nucleotide repeat (UGGAA)n in the Purkinje cell nucleus is
associated with spinocerebellar ataxia type 31 pathogenesis. Neuropathology
2013;33:600–11.
22 Ashizawa T, Anvret M, Baiqet M, et al. Characteristics of intergenerational
contractions of the CTG repeat in myotonic dystrophy. Am J Hum Genet
1994;54:414–23.
23 Wheeler VC, Persichetti F, McNeil SM, et al. Factors associated with HD CAG repeat
instability in Huntington disease. J Med Genet 2007;44:695–701.
24 Aziz NA, van Belzen MJ, Coops ID, et al. Parent-of-origin differences of mutant HTT
CAG repeat instability in Huntington’s disease. Eur J Med Genet 2011;54:
e413–18.
25 Gómez-Tortosa E, Gallego J, Guerrero-López R, et al. C9orf72 hexanucleotide
expansions of 20–22 repeats are associated with frontotemporal deterioration.
Neurology 2013;80:366–70.
26 Lesage S, Le Ber I, Condroyer C, et al. C9orf72 repeat expansions are a rare genetic
cause of parkinsonism. Brain 2013;136:385–91.
27 Parisien M, Major F. The MC-Fold and MC-Sym pipeline infers RNA structure from
sequence data. Nature 2008;452:51–5.
28 Zu T, Gibbens B, Doty NS. et al. Non-ATG-initiated translation directed by
microsatellite expansions. Proc Natl Acad Sci USA 2011;108:260–5.
29 Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated
into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013;339:1335–8.
30 Ash PEA, Bieniek KF, Gendron TF, et al. Unconventional translation of C9orf72
GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron
2013;77:639–46.
31 Todd PK, Oh SY, Krans A, et al. CGG repeat-associated translation mediates
neurodegeneration in fragile X tremor ataxia syndrome. Neuron 2013;78:440–55.
Obayashi M, et al. J Neurol Neurosurg Psychiatry 2015;86:986–995. doi:10.1136/jnnp-2014-309153 995
Neurogenetics
group.bmj.com on May 3, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
expansion
short hexanucleotide GGCCTG repeat
diverse populations and can be caused by a 
Spinocerebellar ataxia type 36 exists in
Ishikawa and Alexandra Dürr
Mizusawa, Ludger Schöls, Thomas Klopstock, Alexis Brice, Kinya 
HidehiroThomas Illig, Johanna Huttenlocher, Yasushi Kita, Yuishin Izumi, 
Alain Vighetto, Virginie Desestret, Christelle Tesson, H-Erich Wichmann,
Monin, Charles Duyckaerts, Nozomu Sato, Nathalie Streichenberger, 
Masato Obayashi, Giovanni Stevanin, Matthis Synofzik, Marie-Lorraine
doi: 10.1136/jnnp-2014-309153
online December 4, 2014
2015 86: 986-995 originally publishedJ Neurol Neurosurg Psychiatry 
 http://jnnp.bmj.com/content/86/9/986





Supplementary material can be found at: 
References
 #BIBLhttp://jnnp.bmj.com/content/86/9/986
This article cites 31 articles, 9 of which you can access for free at: 
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1390)Memory disorders (psychiatry)
 (542)Spinal cord
 (183)Neuropathology
 (670)Brain stem / cerebellum
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on May 3, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
